Bozek A, Miodonska M, Sadowska D, Zalejska Fijolka J, et al. Three years treatment with HDM allergen immunotherapy, omalizumab, or combination therapy in allergic asthma: clinical outcomes and biomarkers. J Asthma 2026 Apr 15:1-18. doi: 10.1080/02770903.2026.2660096.
PMID: 41983924